STRESS PREDICTS TRAJECTORIES OF PSYCHOLOGICAL AND PHYSICAL FUNCTIONING IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Goyal, Neha [1 ]
Westbrook, Travis [2 ]
Andersen, Barbara L. [2 ]
机构：
[1] VA Palo Alto, Cupertino, CA USA
[2] Ohio State Univ, Columbus, OH 43210 USA
来源：
ANNALS OF BEHAVIORAL MEDICINE | 2016年 / 50卷
关键词：
D O I：
暂无
中图分类号：
B84 [心理学];
学科分类号：
04 ; 0402 ;
摘要：
D004
引用
下载
收藏
页码：S288 / S288
页数：1
相关论文
共 50 条
  • [41] Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy
    Nikolaenko, Liana
    Liu, Tingting
    Danilov, Alexey V.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (05) : 481 - 487
  • [42] Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies
    Rainone, Michael
    Siddiqi, Tanya
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (01) : 39 - 45
  • [43] ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
    Hillmen, Peter
    Brown, Jennifer R.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Wu, Kenneth
    Cohen, Aileen
    Huang, Jane
    Tam, Constantine S.
    FUTURE ONCOLOGY, 2020, 16 (10) : 517 - 523
  • [44] Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies
    Michael Rainone
    Tanya Siddiqi
    Current Hematologic Malignancy Reports, 2022, 17 : 39 - 45
  • [45] Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review
    Islam, Prioty
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (09) : 1259 - 1273
  • [46] Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
    Costa, Luciano J.
    Fanning, Suzanne R.
    Stephenson, Joe, Jr.
    Afrin, Lawrence B.
    Kistner-Griffin, Emily
    Bentz, Tricia A.
    Stuart, Robert K.
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 645 - 649
  • [47] Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review
    Prioty Islam
    Current Treatment Options in Oncology, 2023, 24 : 1259 - 1273
  • [48] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kang, Dong-Won
    Wang, Li
    Short, Nicholas J.
    Ferrajoli, Alessandra
    Wang, Yucai
    Zhou, Shouhao
    Shen, Chan
    PHARMACOECONOMICS, 2024, 42 (04) : 409 - 418
  • [49] Lenalidomide is an active agent in relapsed and treatment-refractory chronic lymphocytic leukemia
    Ferrajoh, A.
    O'Brien, S.
    Faderl, S.
    Wierda, W.
    Lee, B.
    Reuben, J.
    Schlette, E.
    Estrov, Z.
    Keating, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 130 - 130
  • [50] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
    Hillmen, Peter
    Rawstron, Andy C.
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca J.
    Bishop, Rebecca
    Boucher, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2722 - +
12345